Analyst Price Targets — IPSC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 12:24 pm | Daina Graybosch | Leerink Partners | $2.00 | $2.52 | StreetInsider | Leerink Partners Reiterates Market Perform Rating on Century Therapeutics (IPSC) |
| January 20, 2026 11:50 am | — | Piper Sandler | $4.00 | $2.17 | TheFly | Century Therapeutics price target raised to $4 from $2 at Piper Sandler |
| November 6, 2024 11:41 am | Mitchell Kapoor | H.C. Wainwright | $5.00 | $1.39 | StreetInsider | Century Therapeutics (IPSC) PT Lowered to $5 at H.C. Wainwright |
| April 12, 2024 7:02 am | Edward Tenthoff | Piper Sandler | $9.00 | $4.05 | StreetInsider | Century Therapeutics (IPSC) PT Lowered to $9 at Piper Sandler |
| January 5, 2023 9:48 pm | Edward Tenthoff | Piper Sandler | $14.00 | $4.84 | TheFly | Century Therapeutics price target lowered to $14 from $24 at Piper Sandler |
| December 27, 2022 5:35 am | Geulah Livshits | Chardan Capital | $19.00 | $5.67 | TheFly | Century Therapeutics initiated with a Buy at Chardan |
| November 14, 2022 6:24 am | — | H.C. Wainwright | $25.00 | $11.00 | Benzinga | HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $25 |
| April 29, 2022 5:38 am | — | Leerink Partners | $27.00 | $12.03 | Benzinga | SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $27 |
Latest News for IPSC
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™…
Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models Allo-Evasion 5. 0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppression Phase 1 clinical manufacturing process…
NORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the appointment of Brent Pfeiffenberger, PharmD, MBA, to the Company's Board of Directors.
PHILADELPHIA, May 13, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the first quarter ended March 31, 2026, and recent business highlights.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IPSC.
U.S. House Trading
No House trades found for IPSC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.